Researchers have recently suggested that nicotine and carcinogen exposure as measured by biomarkers such as cotinine and NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) does not vary with cigarettes smoked per day (CPD) among Black smokers. Researchers have also suggested that nicotine exposure does not differ between menthol and nonmenthol smokers. In this study, we examine NNAL exposure for U.S. smokers by race, CPD, and menthol cigarette use.
Methods:
We analyzed urinary NNAL concentrations for more than 1500 everyday smokers participating in the National Health and Nutrition Examination Survey from [2007] [2008] [2009] [2010] . For purposes of comparison, we also analyzed serum cotinine concentrations for these smokers. We used linear regression analysis to estimate mean biomarker concentrations by CPD and race/ ethnicity group and to examine the association between biomarker concentrations and menthol cigarette use by race/ethnicity group, controlling for other demographic and smoking characteristics. results: Biomarker concentrations increased with CPD for White, Black, and Hispanic smokers although NNAL concentrations leveled off for Black smokers at lower CPD levels compared with other smokers. Mean NNAL concentrations were lower among menthol smokers compared with nonmenthol smokers among smokers overall (β = −0.165, p = .032) and White smokers (β = −0.207, p = .048).
Conclusions:
We find evidence in national health survey data that nicotine and carcinogen exposure generally increases with CPD across race/ethnicity groups although the pattern of NNAL exposure differs by race/ethnicity group at high CPD levels. We also find evidence of differences in NNAL exposure for menthol smokers compared with nonmenthol smokers among smokers overall and White smokers.
intrOdUCtiOn
Researchers have noted differences in nicotine and carcinogen exposure and metabolism by race among U.S. smokers for some time. Numerous studies have found higher concentrations of cotinine, a metabolite of nicotine, among Black smokers compared with White smokers who smoked the same number of cigarettes (Ahijevych & Gillespie, 1997; Caraballo et al., 1998; Wagenknecht et al., 1990) . Some studies have found a similar pattern for the tobacco-specific nitrosamine NNAL among Black and White smokers (Muscat, Djordjevic, Colosimo, Stellman, & Richie, Jr., 2005; Richie, Jr. et al., 1997) . Researchers have also found slower clearance of cotinine among Black smokers compared with White smokers (Pérez-Stable, Herrera, Jacob, III, & Benowitz, 1998) and some evidence of slower glucuronidation of NNAL among Black smokers compared with White smokers (Muscat et al., 2005) .
Recent research has once again directed attention to the subject of nicotine and carcinogen exposure by race among US smokers. Benowitz, Dains, Dempsey, Wilson, and Jacob (2011) recently published results from a study of 128 smokers from the San Francisco area. They found that concentrations of biomarkers of nicotine and carcinogen exposure generally did not increase with increased cigarettes per day (CPD) among Black smokers. Caraballo et al. (2011) examined cotinine concentrations among 1943 smokers in the National Health and Nutrition Examination Survey (NHANES) to see if menthol cigarette use contributes to higher observed cotinine levels among Black smokers compared with White smokers. They concluded that cotinine concentrations were not higher for menthol smokers compared with nonmenthol smokers among both Black and White smokers. Other, smaller studies have found similar results for menthol and nonmenthol smokers among White and Black smokers (Heck, 2009; Signorello, Cai, Tarone, McLaughlin, & Blot, 2009) .
In this study, we analyze NNAL and cotinine concentrations for smokers by race/ethnicity, CPD, and menthol cigarette use using 2007-2010 NHANES data. We focus on NNAL exposure, given that differences in NNAL exposure among smokers have been less widely studied than differences in cotinine exposure. NNAL and cotinine are two important and widely studied biomarkers of nicotine and carcinogen exposure. NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), is a metabolite of the tobacco-specific nitrosamine NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (Xia, Bernert, Jain, Ashley, & Pirkle, 2011) . NNK, or nicotine-derived nitrosaminoketone, is formed by the nitrosation of nicotine (Hecht, 2002) . Both NNK and NNAL are known lung carcinogens (Hecht, 2002) . The half-life of NNAL has been estimated to be 10-18 days (Goniewicz et al., 2009) . Cotinine is the primary proximate metabolite of nicotine, with a half-life of 15-20 hr (Benowitz & Jacob, III, 1994; Caraballo et al., 2011) . Its availability in blood, urine, and saliva makes it a useful and widely used biomarker of nicotine exposure (Caraballo et al., 2011) .
Menthol is a common additive and flavoring in cigarettes. Menthol smokers are more likely to be young, female, and Black than nonmenthol smokers (Lawrence et al., 2010) . Understanding nicotine and carcinogen exposure among menthol smokers compared with nonmenthol smokers is an important issue at the present time given that the Food and Drug Administration has been examining the public health impact of menthol cigarettes. Moreover, recent research by Blot, Cohen, McLaughlin, Hargreaves, and Signorello (2011) and Rostron (2012) has found that menthol smoking is associated with lower lung cancer mortality risks compared with nonmenthol smoking, particularly among Black smokers. It is therefore very useful and relevant to examine the concentrations of a known lung carcinogen in NNAL as they relate to race/ethnicity, CPD, and menthol cigarette use.
This study presents several innovative contributions to research in the field. We analyze NNAL and cotinine concentrations by CPD and race/ethnicity using NHANES data. We utilize a nationally representative study population and have a larger sample size than previous studies on this topic, analyzing biomarker concentrations for more than 1500 smokers. We can thus examine NNAL exposure by CPD and race/ethnicity in greater detail than has been done previously. Joseph et al. (2005) , for example, analyzed concentrations of tobacco biomarkers such as cotinine and NNAL by CPD, but these researchers only had data for 400 smokers and did not present results by race. Xia et al. analyzed NNAL concentrations for smokers using 2007-2008 NHANES but did not specifically look at differences by CPD and race/ethnicity. We also analyze biomarkers concentrations by menthol cigarette use. This type of analysis has been done previously for cotinine with NHANES data (Caraballo et al., 2011) but not specifically for NNAL.
MethOds
We analyzed urinary total NNAL and serum cotinine concentrations for U.S. adult smokers using the National Health and Nutrition Examination Survey (NHANES). NHANES is a nationally representative household health survey of the U.S. civilian noninstitutionalized population that is conducted by the National Center for Health Statistics (2011b) . We analyzed data from the 2007-2010 continuous NHANES (National Center for Health Statistics, 2011a). Approximately, 10,000 individuals participated in the NHANES during each 2-year cycle during the period, and participants both completed questionnaires about their health histories and underwent physical examinations that provided urine and serum samples that were subsequently analyzed. NHANES participants aged 12 years and older were asked about tobacco use. We restricted our analyses to cigarette smokers aged 20 years and older to examine nicotine and carcinogen exposure among adult smokers. All analyses were conducted using R version 2.15.0 (R Development Core Team, 2012) and the survey package (Lumley, 2012) , using the appropriate NHANES person-weights and taking into account the NHANES complex survey design.
We analyzed the relationship between biomarker exposure and CPD in several ways. We restricted all analyses to everyday smokers who had smoked on the day of the examination to enhance comparability of estimates across groups. Approximately, 85% of NHANES current smokers reported that they smoked every day, and approximately, 90% of these everyday smokers reported that they had smoked on the day of the examination. We excluded smokers from the analyses if they also reported using pipes, cigars, chewing tobacco, snuff, or nicotine replacement products in the past five days. 1614 NHANES smokers met these criteria, and NNAL and cotinine concentrations were available for 1517 and 1528 of them, respectively. We began our analysis by plotting smooth curves of biomarker exposure as a function of CPD by race/ethnicity group using a locally weighted polynomial regression (LOESS) function with span equal to 0.75. We used NNAL concentrations that had been adjusted for urinary creatinine concentrations. NHANES has oversampled Hispanics generally since 2007, thus allowing for nationally representative estimates for this group (National Center for Health Statistics, 2010), so we plotted curves for non-Hispanics Whites or "Whites," non-Hispanic Blacks or "Blacks," and Hispanics. We measured CPD as the average number of cigarettes that smokers reported having smoked on days that they had smoked in the past five days.
LOESS curves indicated that the relationship between NNAL concentrations and CPD tended to be linear or curvilinear by race/ethnicity group. We therefore conducted linear regression analyses of creatinine-corrected NNAL concentrations by race/ ethnicity group with linear and quadratic CPD terms as predictor variables. We log transformed the NNAL concentrations to reduce skewness. We also controlled for sex, age, and body mass index (BMI) in the analyses. We then calculated predicted NNAL concentrations by CPD, sex, and race/ethnicity with age (45 years) and BMI (28) set to the mean values for the overall group of smokers. 1509 smokers had information for all of the variables and were included in the analysis. We acknowledge that other techniques such as fractional polynomial regression modeling or nonlinear regression modeling could also be used to properly specify the model's functional form. Caraballo et al (1998) , for example, modeled serum cotinine concentrations using a nonlinear regression approach with an asymptotic term for maximum cotinine concentration. We did not use this particular approach, given that the LOESS curves indicated that NNAL concentrations were not necessarily asymptotic for some race/ethnicity groups, even at high CPD levels.
We also examined the relationship between biomarkers and menthol cigarette use for the NHANES smokers using linear regression analysis. We used log biomarker levels as the dependent variables in the analyses. We included menthol or nonmenthol cigarette use and linear and quadratic terms for CPD as independent variables in the analyses. NHANES smokers were asked to identify if they were menthol smokers by presenting a pack of the brand of cigarettes that they usually smoked, reporting the brand of cigarettes that they usually smoked, or reporting that their usual brand of cigarettes was mentholated. Approximately, 95% of NHANES smokers provided information that identified them as menthol or nonmenthol smokers. We again measured CPD as the number of CPD that smokers reported having smoked in the past five days. We included age, BMI, survey year, and urinary creatinine concentrations as continuous control variables in the analyses and sex as a categorical control variable. We included the NHANES race/ethnicity groups (non-Hispanic White or "White," non-Hispanic Black or "Black," Mexican American, other Hispanic, and other race or multiracial) as control variables in the regression analyses for smokers overall. 1447 and 1452 smokers had information for all of the variables and were included in the NNAL and cotinine analysis, respectively. We also conducted separate analyses for each biomarker for each of the race/ethnicity groups and Hispanics generally. We examined the robustness of our results by conducting additional analyses with different model and data specifications. For example, we conducted the analyses including all current smokers and controlled for frequency of cigarette use ("every day" or "some days") and date of last cigarette use ("today," "yesterday," or "3-5 days ago"). We also tested the inclusion of Federal Trade Commission (FTC) nicotine yields for participants' usual cigarette brand as a control variable in the regression analyses. Machine yield measures of nicotine for cigarettes, such as FTC yields, are known to be inaccurate measures of nicotine exposure among actual smokers (Benowitz et al., 1983; Jarvis, Boreham, Primatesta, Feyerabend, & Bryant, 2001 ). Inclusion of FTC yields in the analyses did not substantially affect the results, and we did not include the variable in the analyses presented here.
resUlts Table 1 presents basic descriptive statistics for the NHANES smokers. Hispanic smokers tended to be younger than other smokers, and menthol prevalence was high among Black smokers, as expected. Nonmenthol smokers smoked more CPD than menthol smokers, although this pattern was only observed among White smokers by race/ethnicity group. Black smokers tended to have higher serum cotinine concentrations than other smokers, as has been noted previously (Caraballo et al., 1998) . Nonmenthol smokers had higher mean NNAL concentration compared with White menthol smokers among White smokers and smokers overall. Figure 1a presents smooth LOESS curves for NNAL and cotinine concentrations by race/ethnicity and CPD. The pattern of NNAL concentration by CPD indicates some variation by race/ethnicity. NNAL concentrations generally increased for White and Black smokers from 1 to 15 CPD, but concentrations then leveled off at higher CPD levels for Black smokers while continuing to increase for White smokers. NNAL concentrations generally increased with CPD for Hispanic smokers in a manner similar to White smokers, although the concentrations for Hispanic smokers were generally lower than the concentrations for White smokers at the same CPD levels. Figure 1b shows the same type of curves for cotinine. Black smokers generally had higher cotinine concentrations than other smokers at the same CPD level, but the patterns of cotinine concentrations by CPD were similar for each race/ ethnicity group. Concentrations for each group generally leveled off above 15 CPD. Table 2 presents predicted biomarker concentrations by sex, race/ethnicity, and CPD, adjusted by demographic and smoking characteristics. Predicted NNAL concentrations among White and Hispanic smokers were similar and consistently increased with CPD. NNAL concentrations among Black smokers increased from 5 to 15 CPD, but not necessarily from 15 to 25 CPD, and estimated NNAL concentrations for Black smokers were lower at high CPD compared with White and Hispanic smokers. Cotinine concentrations also leveled off at high CPD among Black smokers, but not among White or Hispanic smokers. Table 3 presents results from regression analyses of the association between biomarker concentrations and menthol cigarette use, adjusted for other demographic and smoking characteristics. Menthol cigarette use was associated with lower NNAL concentrations among smokers overall. This difference was principally due to lower NNAL concentrations for menthol smokers compared with nonmenthol smokers among White smokers. We also obtained similar results when all current smokers were included in the regression analyses (among all smokers, β = −0.140, p value = .043 and among White smokers, β = −0.249, p value = .022). It should be noted that menthol smokers had higher NNAL concentrations compared with nonmenthol smokers among Mexican-American smokers (β = 0.602, p value = .017) and nonsignificantly higher cotinine concentrations (β = 0.323, p value = .091). The small sample sizes for this group (for example, there were 100 nonmenthol smokers and 19 menthol smokers in the NNAL analysis) make it difficult to draw inferences from these data at this point. NNAL concentrations were not elevated for menthol smokers in the analysis for Hispanic smokers overall. In the analysis for smokers overall, NNAL concentrations were higher for women compared with men (β = 0.285, p value = .00007) and with each additional year of age (β = 0.009, p value = .0006). We also obtained similar results for cotinine in analyses of smokers from the 1999-2010 NHANES.
disCUssiOn
We have found using national health survey data that nicotine and carcinogen exposure as measured by NNAL and cotinine generally increases with CPD across race/ethnicity groups for U.S. smokers. We have also found that the patterns of these biomarker concentrations differ by race/ethnicity at high CPD levels. Specifically, we have found that biomarker concentrations level off more sharply for Black smokers compared with White and Hispanic smokers, particularly for NNAL. Black smokers thus have lower NNAL concentrations than White smokers at CPD levels such as 25 in both observed and adjusted data. The causes of this pattern of NNAL concentrations among Black smokers are not clear. Possible causes include misreporting of CPD and differences in metabolism and clearance of NNK and NNAL among Black smokers. Menthol cigarette use does not appear to be a contributing factor, given that NNAL concentrations for Black smokers at high CPD levels are similar for menthol and nonmenthol smokers. We did not find evidence to support the recent finding by Benowitz et al. (2011) that nicotine and carcinogen biomarker concentrations did not increase with CPD among Black smokers in a small study population, given that we found that biomarker concentrations increased for Black smokers from low to medium CPD levels. For example, observed geometric mean cotinine concentrations among Black smokers increased from 261 ng/mL (95% CI = 244-279) for 1-10 CPD to 342 ng/mL (95% CI = 324-362) for 11-20 CPD, but did not necessarily increase for >20 CPD (336 ng/mL, 95% CI = 284-398) It is not entirely clear why our results for Black smokers with low CPD differ from those of Benowitz et al. (2011) . Their study did have a much smaller sample size. For example, they analyzed biomarker concentrations for 15 Black smokers and 11 White smokers with 1-10 CPD and 16 Black smokers and 16 White smokers with >20 CPD. Benowitz et al. also recruited study participants who reported having smoked 10 or more CPD for the past year or longer. It is possible that Black smokers in the 1-10 CPD group in their study were accustomed to smoking larger numbers of CPD and modified their smoking behavior to increase and regulate their nicotine exposure even while smoking fewer cigarettes in the 3 days prior to the study. It is not clear, however, why this compensatory behavior would occur in Black but not White smokers. It is also possible that the different patterns observed in this study and in Benowitz et al. could result in part from the differences involved in the recruitment, examination, and compensation of study participants in a clinical study of the type conducted by Benowitz et al. as opposed to a national health survey such as NHANES.
We also found some associations between NNAL concentrations and menthol cigarette use in adjusted regression analysis. NNAL concentrations were lower for menthol smokers compared with nonmenthol smokers among White smokers and smokers overall. These results are consistent with the nonsignificant increase in NNAL concentrations for nonmenthol smoking compared with menthol smoking (β = 0.0645, Note. The regression analyses control for cigarettes per day (CPD), CPD squared, sex, age, race/ethnicity, survey year, and body mass index. The analyses for NNAL also control for urinary creatinine concentration.
p value = .095) that Xia et al. (2011) found in a regression analysis of 2007-2008 NHANES smokers. Our estimates are specifically for current everyday smokers, but we also obtained similar results in analyses that included occasional or some day smokers. NNAL concentrations were higher for menthol smokers compared with nonmenthol smokers among Mexican Americans, although the sample size was rather limited. No difference in cotinine concentrations was associated with menthol smoking among smokers overall or for smokers by race/ethnicity group. Further study is needed to confirm and understand these results. Research is particularly needed to establish whether or not NNAL exposure truly differs at high CPD for Black smokers compared with other smokers. Several previous studies (Caraballo et al., 1998; Joseph et al., 2005; O'Connor et al., 2006) have found that nicotine and carcinogen biomarker concentrations tend to level off at high CPD for U.S. smokers generally, but it is not clear at this time if these patterns are more pronounced for certain race/ethnicity groups.
Limitations of this study include the relatively modest number of NNAL concentrations that are currently available for NHANES participants, particularly for race/ethnicity and menthol cigarette use subgroups. This condition will improve in future years as data for more participants are analyzed and released. If the results presented here are confirmed, then research will be needed to identify the factors such as smoking behavior, product design, or metabolic activity that contribute to them.
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